Respiratory Pathophysiology of Mechanically Ventilated Patients with COVID-19: A Cohort Study.

To the Editor:

Five to twenty percent of hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are admitted to the ICU, with mortality reported between 26% and 61.5% (1–3). Nearly all ICU patients present with respiratory failure, and up to 88% are managed with invasive mechanical ventilation (1–3).

Descriptions of the pathophysiological characteristics of coronavirus disease (COVID-19) respiratory failure are limited. Reports of preserved respiratory system mechanics despite severe hypoxemia in early small series have led some investigators to hypothesize that a significant proportion of COVID-19 respiratory failure is not the typical acute respiratory distress syndrome (ARDS) and warrants alternative management (4, 5).

A detailed characterization of COVID-19 respiratory failure and its response to established ARDS therapies is needed before rigorous comparisons of established and new strategies can be contemplated. We describe the respiratory pathophysiology of patients with COVID-19 respiratory failure treated with invasive mechanical ventilation at two tertiary care hospitals in Boston, Massachusetts.

Methods

Population and setting

We studied all adult inpatients with SARS-CoV-2 infection and respiratory failure managed with invasive mechanical ventilation at Massachusetts General Hospital and Beth Israel Deaconess Medical Center between March 11 and March 30, 2020. The studies were granted exemption by the hospital institutional review boards. Informed consent was waived.

Clinical management occurred at the discretion of the treating physician. Hospital treatment guidelines recommended ventilation with Vts of <6 ml/kg predicted body weight, early consideration of prone ventilation for PaO:FiO < 200, and conservative fluid management. Positive end-expiratory pressure (PEEP) was titrated per institutional protocols and included use of the lower-PEEP/higher-FiO ARDS network table, titration by best tidal compliance, and esophageal manometry (6). Both institutions recommended against the routine use of high-flow nasal cannula or noninvasive positive-pressure ventilation.

Data collection and definitions

Data were collected from the electronic medical records. ARDS was defined according to the Berlin criteria (7). We estimated the physiological dead-space fraction using the unadjusted Harris-Benedict estimate of resting energy expenditure and the rearranged Weir equation for CO2 production (8). We calculated the ventilatory ratio as previously described (9).

Statistical analysis

We used descriptive statistics to summarize the clinical data. The results are reported as medians and interquartile ranges (IQRs). Categorical variables are reported as counts and percentages. We report all available data without imputation. We performed analyses with GraphPad Prism v7.0 software.

Results

Demographic and clinical characteristics

From March 11 to March 30, 2020, 66 patients with laboratory-confirmed COVID-19 were intubated and admitted to ICUs at Massachusetts General Hospital and Beth Israel Deaconess Medical Center. The patients’ demographics, clinical characteristics, therapies, and outcomes are summarized in Table 1. The median age was 58 years (range, 23–87 yr), and 43 patients (65%) were male. Eight patients (12%) had preexisting pulmonary disease, and 22 patients (34%) were current or former smokers.

Table 1.

Patient Characteristics and Laboratory Values on Hospital Presentation

Characteristics	All Patients
	Percentage of Patients* (N = 66)	Number of Patients
Site
Massachusetts General Hospital	73%	48/66
Beth Israel Deaconess Medical Center	27%	18/66
Demographics
Age, yr, median (range)	58 (23–87)	66/66
Sex, n (%)
Male	65%	43/66
Body mass index, median (IQR)	30 (27–35)	66/66
Comorbidities
Pulmonary disease	12%	8/66
Current smoker or former smoker	34%	22/64
Hypertension	44%	29/66
Diabetes mellitus	26%	17/66
Chronic kidney disease	6%	4/66
Immunocompromise	9%	6/66
Malignancy	8%	5/66
Home medications
ACEi or ARB	27%	18/66
Statin	34%	21/62
Presentation
Symptom onset to admission, d, median (IQR)	7 (6–10)	66/66
Symptom onset to intubation, d, median (IQR)	8 (6–10)	66/66
Presenting symptoms
Fever	86%	57/66
Cough	88%	58/66
Dyspnea	91%	60/66
Congestion	15%	10/65
Nausea/vomiting	22%	14/65
Diarrhea	28%	18/65
Myalgias	55%	36/66
Fatigue	67%	44/66
Presenting laboratory values, median (IQR)
White blood cell count, 1,000/mm3	7.6 (5.7–9.7)	65/66
Lymphocyte count, 1,000/mm3	0.93 (0.66–1.16)	65/66
C-reactive protein, mg/L	159 (88–233)	57/66
Ferritin, μg/L	923 (590–1,548)	52/66
D-dimer, ng/ml	1,144 (789–2,440)	50/66
Lactate dehydrogenase, IU/L	442 (351–584)	54/66
Creatine kinase, U/L	210 (107–395)	42/66
IL-6, pg/ml	126.7 (65.0–343.0)	46/66
Respiratory parameters on intubation
Bilateral infiltrates on chest X-ray	97%	64/66
PaO2:FiO2, median (IQR)	182 (135–245)	65/66
Estimated physiological dead-space fraction, median (IQR)	0.45 (0.38–0.58)	65/66
Ventilatory ratio, median (IQR)	1.25 (1.06–1.44)	65/66
Ventilator parameters on intubation, median (IQR)
Positive end-expiratory pressure, cm H2O	10 (8–12)	66/66
Plateau pressure, cm H2O	21 (19–26)	48/66
Driving pressure, cm H2O	11 (9–12)	48/66
Static compliance, ml/cm H2O	35 (30–43)	48/66
Resistance, cm H2O/L/s	5 (4–7)	48/66
ICU therapies
High-flow nasal cannula	2%	1/66
Non-invasive positive pressure ventilation	2%	1/66
Invasive mechanical ventilation	100%	66/66
Invasive mechanical ventilation, HD initiated, median (IQR)	1 (1–2)
Prone position	47%	31/66
Prone position, HD initiated, median (IQR)	3 (2–5)
Neuromuscular blockade	42%	28/66
Neuromuscular blockade, HD initiated, median (IQR)	2 (1–2)
Inhaled pulmonary vasodilator	27%	18/66
Inhaled pulmonary vasodilator, HD initiated, median (IQR)	3 (1–3)
Extracorporeal membrane oxygenation	5%	3/66
Extracorporeal membrane oxygenation, HD initiated, median (range)	2 (2–5)
Renal replacement therapy	20%	13/66
Renal replacement therapy, HD initiated, median (IQR)	9 (5–13)
Vasopressors	95%	63/66
Selected inpatient medications
Antibiotics	98%	65/66
Glucocorticoids	8%	5/66
Statins	82%	54/66
Hydroxychloroquine	91%	60/66
Azithromycin	97%	64/66
Remdesevir (or placebo)	26%	17/66
Lopinavir/ritonavir	3%	2/66
Anti–IL-6 antibody	11%	7/66
Outcomes
Patient follow-up, d, median (range)	34 (30–49)	66/66
Successful extubation	62.1%	41/66
Duration of mechanical ventilation, d, median (IQR)†	16.0 (10.0–21.0)
Tracheostomy	21.2%	14/66
Time to tracheostomy, d, median (IQR)	22.5 (18.0–27.0)
Thrombotic event	22.7%	15/66
ICU discharge	75.8%	50/66
ICU length of stay, d, median (IQR)‡	17.5 (13.0–25.0)
Death	16.7%	11/66

Definition of abbreviations: ACEi = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; HD = hospital day; IQR = interquartile range.

Unless otherwise indicated.

Among patients who did not have tracheostomy placement.

Among patients who were discharged from the ICU.

Respiratory failure and respiratory system indices

Gas exchange and respiratory system mechanics are shown in Figure 1. On ICU admission, 56 patients (85%) met the Berlin criteria for ARDS, and most patients had mild-to-moderate ARDS (7). On intubation, the median PEEP was 10 cm H2O (IQR, 8–12), plateau pressure was 21 cm H2O (IQR, 19–26), and driving pressure was 11 cm H2O (IQR, 9–12). The static compliance of the respiratory system was 35 ml/cm H2O (IQR, 30–43). The estimated physiologic dead-space ratio was 0.45 (IQR, 0.38–0.58).

Figure 1.

Respiratory indices during the first 5 days of mechanical ventilation. Respiratory indices, including the PaO:FiO ratio, plateau pressure (Pplat), positive end-expiratory pressure (PEEP), and static compliance of the respiratory system (CstatRS), were obtained daily in intubated patients with coronavirus disease (COVID-19) respiratory failure. The number of patients with recorded values is shown below the x-axis. The solid line indicates the median value.

Response to prone ventilation

Among the 31 patients who underwent prone ventilation, the median PaO:FiO ratio in the supine position was 150 (IQR, 125–183) and compliance was 33 ml/cm H2O (IQR, 26–46 ml/cm H2O) immediately before prone positioning. After prone positioning, PaO:FiO increased to 232 (IQR, 174–304) and compliance increased to 36 ml/cm H2O (IQR, 33–44 ml/cm H2O). After the patients returned to the supine position, PaO:FiO was 217 (IQR, 149–263) and compliance was 35 ml/cm H2O (IQR, 31–41 ml/cm H2O). Seventy-two hours after initial prone ventilation, the patients had a PaO:FiO while supine of 233 (IQR, 167–265) and compliance of 42 ml/cm H2O (IQR, 34–47 ml/cm H2O). Over these 72 hours, the patients underwent prone ventilation for a median of two sessions (range, 1–3), with a median of 18 hours (IQR, 16–22 h) per session. Twelve patients (38.7%) received concurrent neuromuscular blockade. The median PEEP was 13 cm H2O (IQR, 12–15 cm H2O) while supine at all time points, and 14 cm H2O (IQR, 12–15 cm H2O) in the prone position.

Outcomes

As of data censoring on April 28, 2020, the median patient follow-up was 34 days (range, 30–49 d; Table 1). Forty-one patients (62.1%) were successfully extubated, and among these patients the median duration of mechanical ventilation was 16.0 days (IQR, 10.0–21.0 d). Fourteen patients (21.2%) underwent tracheostomy. Fifty patients (75.8%) were discharged from the ICU. Eleven patients (16.7%) died.

Discussion

We characterized COVID-19 respiratory failure in 66 patients managed with mechanical ventilation and established ARDS protocols. Almost all of the patients presented with dyspnea and were intubated on the day of hospital presentation. Upon initiation of mechanical ventilation, the patients had a median PaO:FiO of 182, dead-space fraction of 0.45, and compliance of 35 ml/cm H2O—findings that are consistent with previously described large cohorts of patients with ARDS (6, 8, 10). The patients exhibited a spectrum of impaired gas exchange and respiratory system mechanics, and very few patients had near-normal compliance (Figure 1). Improvements in oxygenation and compliance with prone positioning were consistent with prior studies of prone ventilation in early ARDS (10). Prone ventilation improves gas exchange in ARDS by increasing aerated areas of the lung, among other mechanisms (11). Our findings thus differ from earlier series describing near-normal respiratory system compliance and a lack of recruitability in early presentations of COVID-19 respiratory failure (4, 5). The patients in our cohort were managed with established ARDS therapies, including low Vt ventilation, conservative fluid administration, and, in many cases, prone ventilation. With a minimum follow-up of 30 days, overall mortality was 16.7% and the majority of the patients were successfully extubated and discharged from the ICU.

Our study has important limitations. The limited duration of patient follow-up in this retrospective study was driven by a focus on respiratory pathophysiology as opposed to clinical outcomes. Furthermore, it is possible that some patients were not intubated for reasons related to goals and preferences, and thus were not included in our cohort.

Patients with COVID-19 respiratory failure in our series exhibited gas exchange values, respiratory system mechanics, and responses to prone ventilation similar to those observed in large cohorts of patients with ARDS. Although further study is needed to elucidate the biology and unique features of this disease, our findings provide a pathophysiologic justification for the use of established ARDS therapies, including low Vt and early prone ventilation, for COVID-19 respiratory failure.